Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.10p -0.94% 10.50p 10.00p 11.00p 10.60p 10.50p 10.60p 93,153 11:24:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.8 -0.5 -0.2 - 22.00

Eden Research Share Discussion Threads

Showing 6876 to 6900 of 7400 messages
Chat Pages: Latest  284  283  282  281  280  279  278  277  276  275  274  273  Older
DateSubjectAuthorDiscuss
27/4/2019
18:40
Can we not get Sipcam to write on the Eden website the EXACT translation they have put up on their website. It certainly merits applause on how to do things properly. Makes the BOD look like amateurs. Congratulations Sipcam.
chrischas
27/4/2019
17:20
As I understand it, there is no Go-E. So to me it would me an incorrect label on their website.
investingisatrickygame
27/4/2019
16:57
Yes we have discussed it.. I'm just surprised to see it still being used and wonder why. Could it be to differentiate current GO-E Sipcam/Sumiagro/ Sumitomo products 3LOGY from future SustainE Sipcam plus Collaborator products?
supersonico
27/4/2019
16:29
Sustaine, is the new name for Go-E. This is something we have discussed before. Super, Haven't we established before from Sean Smith in print and on film that the original target numbers quoted for Cedroz in the original December 2016 RNS have risen to $1.2 billion. Therefore, I imagine there is overlap/new applications for Cedroz.
investingisatrickygame
27/4/2019
16:15
Brucie5, I'm not sure because their are Nematicides used pre planting as a fumigant which I believe is/was due to be phased out but since Cedroz is a post planting application I'm unclear as to how much we can extrapolate without further details from Eden as to how the market over laps and whether Cedroz can replace Conventional treatments in all cases. The Emergency approval suggests it might well overlap substantially.. As to how much is a good AGM question imo.
supersonico
27/4/2019
16:12
GO-E on our biggest share holders website. I thought that was old skool. hTTp://www.sipcamitalia.it/it/fungicidi/25/3logy/X/16396?fbclid=IwAR27bwIZ7hLuzGzryIHGE0EOykew3MhYsIC3yqDTIB51-KUZTAieIcMdkTw
supersonico
27/4/2019
16:10
It has been said by someone somewhere, that Eastman was looking to replace its existing nematicide with Cedroz, and the former had 20% market share. Is this a myth, or can anyone confirm?
brucie5
27/4/2019
14:57
Cedroz should get if we understand this properly, a significant market share. Goodbye to shore caps 5%!
investingisatrickygame
27/4/2019
14:46
Again..looking at the sentence below, I'm trying to fathom what it says about the status of other comparable Nematicides in the EU. I assume all EU countries will have had previous access to Nematicides so does this statement acknowledge that all other similar application Nematicides are unsuitable? If so surely all other countries will wish to enact 'emergency authorisations' in the absence of 'suitable commercially-available alternatives'. This suggests to me Italy will not be alone and also means, does it not that Eden have this niche market all to themselves? Italy grants "emergency use" Cedroz authorisation Such "emergency" authorisations are allowed by EU member states when local regulatory authorities judge that they are needed in the local market in order to meet the requirements of growers in the absence of suitable commercially-available alternatives
supersonico
27/4/2019
10:29
Hi AttyG,You could obviously tell I know little about how options work and I thank you for giving me this information.I too hope that they make many millions and that the company pays a healthy dividend.I'd like to see the share price into the pounds, but not just yet. They are cheap to buy just now and I'm still accumulating.
wilmer100
27/4/2019
09:59
Could the other platform be related to the Anti-microbial component that Xinova refer to?
supersonico
27/4/2019
09:46
Hi Wilmer, They will be granted if share price conditions are met in Sept 2019 and 2020. Sean and Alex have a period of time in which to excercise them - from my understanding, as soon as any awarded option is taken up a tax charge will be crystallised (benefit in kind). Such a tax charge may necessitate Sean and or Alex to then sell a quantity of the shares awarded to meet said tax bill. It therefore makes sense not to excercise the award till the last possible date or if they believe the share price has become too toppy and they want to cash in. I am hoping they receive the awards and that they make several millions. My understanding is the sustaine tech is developed by/from/in collaboration with the US uni. Investing raises an intriguing point - if there is another platform to Eden's IP, then it would be good if this was made clear. I am delighted with the granting of the emergency use of Cedroz in Italy. Fingers crossed this means they will get on with providing full continuing use approval in short order. Perhaps we may enjoy more such RNSs in the near future. For me this is a fundamental change in the commercial outlook for Eden - for the better, in case someone doubts the view of a deluded bull!
attyg
27/4/2019
09:37
Mevalone/ Cedroz Italy Approval time Comparison Mevalone EU Product Authorisation 26th May 2015 Approval of 3AEY in Italy 11th Feb 2016 Roughly +/- 9 months Cedroz EU Product Authorisation - Cedroz 20th Feb 2019 Italy grants "emergency use" Cedroz authorisation 26th Apr 2019 Roughly +/- 2 months
supersonico
27/4/2019
09:03
OK. Thanks, as I said my knowledge is not perfect.2027 does seem a long time from now. I'm in this for the long term if possible and have a fantasy that the dividend could be greater than the present share price.Over 5 years invested in this company and still building my share holding.
wilmer100
27/4/2019
08:38
WILMER100 said "I thought 2 million of the options expired September 2019 and a further 2 million September 2020". Those are separate options
investingisatrickygame
27/4/2019
07:14
I thought 2 million of the options expired September 2019 and a further 2 million September 2020.Also I can't see it on their website but I do believe that the 2nd technology platform was obtained from the university of Massachusetts.I could be wrong, my knowledge is not perfect.
wilmer100
27/4/2019
00:14
Printed copy of the 2018 Annual Report I ordered and received a copy today. Firstly, for anyone that doesn't have a copy, I would recommend you get one. It is comprehensive and beautifully presented, in fact an excellent document in print to go to any potential investor and far more impactful than an online PDF version. I have noticed a few interesting things though (not all new) 1) Eden seeks to be the leader in sustainable bioactive products enabled or enhanced by Sustaine. As another poster has mentioned, I would expect Sustaine to be of greater value than developing a long line of bioactive products, but clearly Eden is intent on building a strong product portfolio 2) Eden's proven addressable market is $1.2 billion today, tomorrow it grows to $4 billion not including Sustaine related products. $4 billion is $2 billion bigger than quoted at the Proactive presentation on the 12th February 2019. Slide 18 hxxp://www.edenresearch.com/~/media/Files/E/Eden-Research/documents/reports-and-presentation/eden-presentation-feb-19-proactive.pdf 3) Page 11 of the printed report "Eden is leveraging two technology platforms to provide sustainable solutions". What is the second technology platform as I only know of one.....Sustaine! 4) Sustaine is being tested by some of the major agchem companies. Would it be possible to know who they are as Sipcam is not one of them in my opinion. Bayer is likely one, who are the others? 5) Pages 14 & 15, shareholder engagement. Eden details an "Investor Relations Calendar (typical, rolling)". Aside of the AGM, it is heavily focused towards the City in my opinion. They do say the AGM's are generally well attended. I guess, to be fair, that is subjective, but I wouldn't agree with that given the size of the share register. 6) Sean and Alex between them have 4 million, nil value options expiring 2027, so time really is on their side! 7) For 'Super', page 29, the Bank of New York (nominees) holds 3.37% of the issued share capital 8) Page 3, "our Commercial Partners" continues to position Bayer first, even after many, many, years of delays. Relevant or not? Accepting that it will cost a few quid in printing, it really is well presented and I would be handing it out to every potential interested party. It's a shame that it can't go to every one of our 2,000 registered shareholders as I think it would be reinvigorating for many.
investingisatrickygame
26/4/2019
19:03
I was told this at 10.20am this morning that MM were bidding for 1m shares at 11p. That bid for there for only 15min. Not sure if the particular MM did manage to acquire the shares for his clients. very interesting development.
northwick
26/4/2019
15:06
Brucie5.. Your not the only one. Commiserations to those reading this BB who know this marks an end to their BS commentary. LOL Their will be no Eulogy.
supersonico
26/4/2019
15:05
The Italian local regulatory authorities have judged that "emergency" authorisations are needed in the local market in order to meet the requirements of growers in the absence of suitable commercially-available alternatives. The words "lack of suitable competition" and "open door" spring to mind for Cedroz take-up in Italy. The local regulatory authorities are obviously well informed regarding Cedroz.
weyweyumfozo
26/4/2019
14:58
Yes, indeed, Wan, and brings forward the likelihood of additional income stream for 2019!
brucie5
26/4/2019
14:51
Well, am I the only one to find today's RNS even vaguely exciting? Eastman is really working hard for us, it seems. They seem to have impressed the Italians, who have a huge agricultural sector; never mind the fact that Italy, as the world's largest wine producer is already using Mevalone via Sipcam.
brucie5
26/4/2019
14:43
Super, Your post above is right in that the statement you re-quote should not be underestimated. It is quite a statement and Eden should look to capitalise on the same. However,...… ipeesquint is right in my book about the jam tomorrow, inappropriate and disproportionate pay rises, bonuses and share options that have been awarded. This doesn't say 'we are in it together or our interests are aligned with yours' because they're simply not when the share price is 3 years static and illiquid. That really is a statement suggesting Cedroz is about to grab immediate and significant market share straight out the gate in Italy. Investors are right to be weary with Eden and they will look to exit as soon as. New investors are right to be wary of Eden until delivery changes. I love the Eden story, but I too am getting tired of it. I would love it again though if Eden would drive their share price to many multiples of today's price, today and then we can start to look forward to the forward journey again. The share price is the biggest elephant in the room. So I am all for the pay rises, bonuses and share options, with the former two coming when Eden's share price is north of 30p and the latter exercisable when the shares are 40-50p
investingisatrickygame
26/4/2019
14:28
Ipeesquint, The words of Zach Bush..Autism rates have doubled in the last 6 years to 1 in every 30 kids and by 2030/5 based on current projections 1 in 3 children will be diagnosed as being on the Autistic spectrum. 46% of children have a chronic Health issue. These are end of Empire numbers. @13min hTTps://www.youtube.com/watch?v=X3aOQ0N74PI&fbclid=IwAR08MulF_LQ5oC8iOFsSD_7Nl4F0arIVQVo0s7ewgRlHwardxQCFgnusiys With these sorts of stats routinely thrown around and bio technology rapidly evolving I think were all frustrated. That may well be down to management but I lean more towards NDA's and evolving product development as a reason why were still waiting. The statement we all read today, below, should not be underestimated imo as not only does it show a vacuum in the Green revolution technology, it marks a step change in the leverage our partners have and their confidence that the product performs better than conventional chemistry. It shows the confidence and trust regulators are gaining for Eden technology. It also marks the acceptance and maturity of Eden's tech reputation for Biopesticide products that was not their or was more cautious with Mevalone. As we have all grumbled about the slow progress of the share price the Times have changed before our eyes. The tide is turning in Eden's favour, but not many realise it right now.. but they will. 'Such emergency authorisations are allowed by EU member states when local regulatory authorities judge that they are needed in the local market in order to meet the requirements of growers in the absence of suitable commercially-available alternatives'.
supersonico
26/4/2019
13:56
Investing all true what your saying. I don’t post often as I am a bit weary of Eden having owned quite a pile for so long. I hope one day to get a bit of that future jam but suspect my kids are more likely to benefit when I am gone. It is my worst ever investment and while I still have hope .....it diminishes every time Sean awards an inappropriate and disproportionate pay rise to him and Alex. The AGM used to be an exciting time but of late I find myself bashing my teeth at what comes out of it. Groaning is also a firm favourite and a requirement for a long time holder of which there are surprisingly many. I’m not sure what keeps us here anymore. Good luck all.
ipeesquint
Chat Pages: Latest  284  283  282  281  280  279  278  277  276  275  274  273  Older
Your Recent History
LSE
EDEN
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190626 05:50:03